Regenerative Medical Technology Group AI Stock Analysis
Want to see RMTG full AI Analyst Report?
Regenerative Medical Technology Group (RMTG) AI Stock Analysis
Regenerative Medical Technology Group
(Other OTC:RMTG)
The overall score is at the minimum of 37, reflecting extreme financial distress. The company is technically insolvent with negative equity and high debt, which is the most significant risk factor. This is compounded by deeply bearish technicals and a negative P/E ratio. While recent corporate events point to accelerating revenue growth and a strategic path forward, these positive signals are insufficient to offset the severe and immediate balance sheet risks.
Regenerative Medical Technology Group (RMTG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $463.81K
- Dividend Yield
- ―
- Average Volume (3M)
- 58.56K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -1.58
- Revenue Growth
- 94.32%
- EPS Growth
- -158.38%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Regenerative Medical Technology Group Business Overview & Revenue Model
Company Description
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of st...
Regenerative Medical Technology Group Financial Statement Overview
Summary
Financial health is critically weak. While TTM revenue growth of 47.7% and positive EBITDA are notable, the company is insolvent with negative equity of -$39.3M, high debt relative to assets, and persistent substantial net losses. Cash flow is insufficient, leading to negative free cash flow. The extreme balance sheet risk overshadows operational improvements.
Income Statement
35NegativeBalance Sheet
10Very NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 5.10M | 4.11M | 2.41M | 1.53M | 437.89K |
| Gross Profit | 5.51M | 2.81M | 2.82M | 1.68M | 876.97K | 150.14K |
| EBITDA | 2.00M | -83.56K | 301.74K | -3.01M | -1.02M | -10.11M |
| Net Income | -9.53M | -7.81M | -5.56M | -9.81M | -5.49M | -12.88M |
Balance Sheet | ||||||
| Total Assets | 5.85M | 4.49M | 3.82M | 2.88M | 8.08M | 9.31M |
| Cash, Cash Equivalents and Short-Term Investments | 1.32M | 956.72K | 1.17M | 530.54K | 1.65M | 2.98M |
| Total Debt | 21.74M | 19.57M | 20.05M | 17.65M | 15.14M | 13.37M |
| Total Liabilities | 45.11M | 39.23M | 31.18M | 24.67M | 20.06M | 16.06M |
| Stockholders Equity | -39.26M | -34.75M | -27.36M | -21.80M | -11.98M | -6.76M |
Cash Flow | ||||||
| Free Cash Flow | -582.33K | -1.31M | 635.28K | -804.80K | -1.31M | -9.88M |
| Operating Cash Flow | 268.56K | -706.52K | 850.70K | -419.20K | -1.11M | -9.88M |
| Investing Cash Flow | -850.89K | -602.58K | -215.42K | -385.60K | -198.43K | 666.47K |
| Financing Cash Flow | 291.38K | 1.10M | 0 | -309.85K | -20.78K | 12.15M |
Regenerative Medical Technology Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTG, the sentiment is Neutral. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 57.59 is Neutral, neither overbought nor oversold. The STOCH value of 81.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RMTG.
Regenerative Medical Technology Group Risk Analysis
Regenerative Medical Technology Group disclosed 37 risk factors in its most recent earnings report. Regenerative Medical Technology Group reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksRegenerative Medical Technology Group Peers Comparison
Overall Rating
IVF45Neutral
BJDX44Neutral
WOK43Neutral
RMTG37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $2.36M | -0.16 | -33.77% | ― | 15.16% | 99.98% | |
| 44Neutral | $2.41M | -0.08 | -113.80% | ― | ― | 95.46% | |
| 43Neutral | $5.18M | -0.01 | -18.55% | ― | ― | ― | |
| 37Underperform | $478.12K | -0.04 | 27.29% | ― | 94.32% | -158.38% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RMTG | Regenerative Medical Technology Group Inc. | 0.04 | -0.02 | -41.67% | |
| BBLG | Bone Biologics Corp | 0.28 | -1.06 | -79.32% | |
| IVF | Invo Fertility Inc | 1.76 | -50.56 | -96.64% | |
| BJDX | Bluejay Diagnostics, Inc. | 1.80 | -18.52 | -91.14% | |
| NIVF | Newgenivf Group Limited | 0.04 | -5215.07 | -100.00% | |
| WOK | WORK Medical Technology Group LTD | 1.16 | -43198.85 | -100.00% |
Regenerative Medical Technology Group Corporate Events
Regenerative Medical Technology Group Highlights Growth, Financing Strategy
PositiveOn August 20, 2026, Regenerative Medical Technology Group held a previously announced investor video call in which management addressed shareholder questions about growth, financing, and strategic direction. Executives highlighted strong revenue mome...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
